Skip to main content

Table 1 Patients’ characteristics

From: Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer

 

arm A (n = 25)

arm B (n = 25)

p-value

Sex

  

0.11

 Male

21

16

 

 Female

4

9

 

Age

  

0.81

 median

63

65

 

 range

55-74

45-74

 

Histology

  

0.69

 Adenocarcinoma

17

18

 

 Large cell carcinoma

0

1

 

 Squamous

6

5

 

 Others

2

1

 

Stage

  

0.56

 IIIB

10

8

 

 IV

15

17

 

PS

  

0.54

 0

9

6

 

 1

16

19

Â